In a dramatic turn of events, Anne Wojcicki, co-founder and former CEO of 23andMe, has emerged victorious in a competitive bidding war to regain control of the bankrupt genetic testing company she helped build. 

Wojcicki’s nonprofit organization, TTAM Research Institute, agreed to acquire nearly all of 23andMe’s assets for $305 million, outbidding biotech giant Regeneron Pharmaceuticals.

TTAM Outbids Regeneron in Bankruptcy Sale

Regeneron (NASDAQ:REGN) had initially secured a deal to purchase 23andMe for $256 million. However, Wojcicki returned with a higher $305 million bid, prompting 23andMe to request a second auction to reconsider its options.

This led to the selection of TTAM’s offer, which includes added commitments to consumer privacy and data protection.

“We believe it is critical that individuals are empowered to have choice and transparency with respect to their genetic data,” Wojcicki said in a statement. “They should have the opportunity to continue to learn about their ancestry and health risks as they wish.”

https://usaherald.com/23andme-states-sue-to-block-sale-of-dna-data-during-bankruptcy-battle/

A bankruptcy court hearing is scheduled for June 17, when a judge will review and potentially approve the deal. If approved, the acquisition will likely be finalized in the following weeks.

Background: Who Is Anne Wojcicki?

Anne Wojcicki is a pioneering figure in the field of consumer genetics. In 2006, she co-founded 23andMe to make personal genomics accessible to the public.

 Under her leadership, the company became one of the first to offer direct-to-consumer DNA testing kits, providing insights into ancestry and potential health risks.

Wojcicki, a former healthcare investment analyst, is known for her strong advocacy for genetic privacy and consumer empowerment.

Her return to 23andMe through the TTAM Research Institute signals her ongoing commitment to protecting and expanding public access to personal genetic information.

Legal and Privacy Concerns 

The deal comes amid scrutiny from multiple state attorneys general, who have expressed concern over the potential sale of sensitive DNA data during bankruptcy proceedings.

Lawsuits were filed earlier this year to prevent 23andMe from transferring consumer data without sufficient safeguards.

Reports have highlighted fears that the company might monetize or compromise genetic data, raising red flags about consumer privacy. In response, TTAM has vowed to uphold stringent privacy standards, a move likely to ease public concern.

What’s Next for 23andMe?

If the court approves the sale, TTAM will assume control over the majority of 23andMe’s assets. It is unclear how operations will change under nonprofit ownership. Wojcicki’s leadership is expected to re-center the company's mission around science, transparency, and consumer trust.

Her return may also mark a turning point for the embattled company, which filed for bankruptcy in March after financial struggles and public backlash over privacy concerns. (More here)

For Wojcicki, the move appears both personal and strategic. As she steps back into the genetic spotlight, all eyes are on how she’ll rebuild a brand she once led to prominence—and whether she can regain public trust.